Cardiology

Cardiology

By ReachMDMedicine
Download on the App Store

Cardiology episodes

  • Shifting Treatment Paradigm in HFmrEF/HFpEF: Steroidal and Nonsteroidal MRAs
    Guest: Faiez Zannad, MD, PhD
    Guest: John McMurray, MD

    Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.

    17 min
  • APOC3 Inhibition: A Novel Approach to Lowering TGs
    Guest: Børge G. Nordestgaard, MD, DMSc
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min
  • Targeting Mixed Hyperlipidemia with APOC3 Inhibition
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min
  • SHTG: Defining the Unmet Clinical Need
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min
  • Remnant Cholesterol: The Missing Link in ASCVD risk
    Guest: Børge G. Nordestgaard, MD, DMSc
    Guest: Kausik Ray, MBChB, MD, MPhil

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    3 min
  • Treating Obesity: Lifelong Strategies from Lifestyle to Pharmacotherapy and Surgery Treating Obesity: Lifelong Strategies fFrom Lifestyle to Pharmacotherapy and Surgery
    Guest: Michael Crotty, MB, BCh, BAO
    Guest: Barbara McGowan, PhD, MBBS

    This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

    This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

    6 min
  • Beyond the Scale: How to Tackle Obesity’s Comorbidities
    Guest: Barbara McGowan, PhD, MBBS
    Guest: Ana Maria Cebrián-Cuenca, MD, PhD

    This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

    This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

    5 min
  • Obesity: Unmasking the Chronic Disease Beneath the Weight
    Guest: Michael Crotty, MB, BCh, BAO

    This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care.

    This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

    8 min
  • The Road Ahead: What's on the Horizon for FCS and SHTG Management
    Guest: Pam R. Taub, MD, FACC, FASPC
    Guest: Prof. Kausik Ray

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    5 min
  • FCS: Enhancing the Diagnosis
    Guest: Daniel Gaudet, MD, PhD

    There is an unmet need for patients with FCS, SHTG, and mixed hyperlipidemia, as most patients are non-responsive to current standard of care. Recent developments on APOC3 inhibition show promising results for the management of these patient groups. Four experts discuss the characteristics, diagnostic criteria and the risks of patients with FCS, SHTG, and mixed hyperlipidemia, and review the recent evidence of clinical trials with new APOC3 inhibitors.

    4 min